The JMJD4 Knockout A-549 Polyclonal Cells constitute a polyclonal knockout cell population generated through CRISPR/Cas9-mediated disruption of the JMJD4 gene in the A-549 human lung adenocarcinoma cell line. This loss-of-function model enables investigation of JMJD4-dependent cellular processes, particularly those related to ribosomal protein modification and translation control. As a polyclonal population, the product captures a range of editing events, making it well-suited for experiments requiring bulk cell analyses rather than clonal phenotypes.
A-549 is an adherent epithelial cell line derived from a non-small cell lung carcinoma patient, widely used in cancer research. These cells carry an activating KRAS mutation, reflecting a common genetic alteration in lung adenocarcinoma, and maintain alveolar basal epithelial features. Their robust growth and extensive characterization make them a practical host for generating knockout models to study lung cancer biology and therapeutic responses.
JMJD4 functions as a lysine demethylase specific for ribosomal protein RPS2, a component of the 40S subunit. Demethylation of RPS2 by JMJD4 is regulated by upstream signals, including mTORC1 and MYC, and is essential for ribosome biogenesis and efficient translation initiation. The JMJD4?CRPS2 axis interfaces with translation factors such as eIF2??, linking nutrient-sensing pathways to protein synthesis. Knockout of JMJD4 disrupts this demethylation event, potentially impairing ribosomal function and global translation.
In the A-549 context, loss of JMJD4 provides a relevant system to assess the impact of ribosomal protein methylation on lung cancer cell growth. The knockout is expected to reduce RPS2 demethylation, compromise 40S subunit activity, and attenuate protein synthesis, thereby affecting proliferation and tumorigenic potential. This model allows systematic exploration of how translational control mechanisms contribute to non-small cell lung carcinoma, and may inform strategies targeting ribosomal modifications for therapy.
This polyclonal knockout product can be used in polysome profiling to examine ribosome assembly, Western blotting to detect RPS2 methylation levels, and puromycin incorporation assays to measure translation rates. Cell proliferation assays and RNA-seq further enable phenotypic and transcriptomic analyses. Applications span lung cancer biology, ribosome biogenesis, translation regulation, epigenetic modulation, and drug target identification. For additional details or to place an order, please contact Ascent Research.
